|
Adoptive Cell Therapy for Metastatic Cancer Using Naturally Occurring and Gene-Modified T Cells
Steven A. Rosenberg, National Cancer Institute, Bethesda, MD
Assaying Activation of the Cancer Kinome En Masse
Gary L. Johnson, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC
Biological Responses to Tumor Hypoxia and Their Potential as Therapeutic Targets
Brad G. Wouters, University of Toronto Ontario Cancer Institute, Toronto, ON, Canada
Biology of the Cancer Epigenome: Exploiting the Translational Implications
Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD
Breast Cancer in African American Women: Unanswered Questions
Christine B. Ambrosone, Roswell Park Cancer Institute, Buffalo, NY
Building a Genomic Prescribing System
Mark J. Ratain, University of Chicago, Chicago, IL
The Chemical Basis of Pharmacology
Brian Shoichet, University of California, San Francisco, CA
Chk1 Kinase Inhibitors: How to Enable Cell Cycle Therapies in the Clinic
Peter K. Jackson, Genentech, Inc., South San Francisco, CA
Clinical Implications of the Cancer Stem Cell Hypothesis
Max S. Wicha, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
Clinical Trials of PARP Inhibitors: Do They Work and for Which Patients?
Susan Domchek, Abramson Cancer Center, Philadelphia, PA
Computational and Systems Cancer Biology
Dana Pe'er, Columbia University, New York, NY
Deregulation of Stem Cell Self-Renewal Pathways in Cancer
Michael F. Clarke, Stanford University School of Medicine, Stanford, CA
Development of Therapeutic Cancer Peptide Vaccine and Construction of Translational Research Network: Lessons From Vaccine Treatment of 1,700 Patients
Yusuke Nakamura, University of Tokyo Institute of Medical Science, Tokyo, Japan
DNA Damage Responses: Bedside to Bench to Bedside
Michael B. Kastan, Duke Cancer Institute, Durham, NC
DNA Replication Stress and Genome Instability
Karlene A. Cimprich, Stanford University, Stanford, CA
Dynamic Control of Phosphotyrosine Signaling in Normal and Cancer Cells
Anthony J. Pawson, Mount Sinai Hospital, Toronto, ON, Canada
Empiric and Theoretical Technologies to Personalize Cancer Diagnosis and Treatment
David Sidransky, Johns Hopkins Medical Institutions, Baltimore, MD
Epigenetic Control of Metastatic Prostate Cancer
Karen Cichowski, Brigham and Women's Hospital, Boston, MA
Epigenetic Deregulation in AML
Maria E. Figueroa, University of Michigan, Ann Arbor, MI
Functional and Integrated Genomics in Cancer
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA
Genetic Epidemiology of Ovarian Cancer: Past and Present
Thomas A. Sellers, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Genetic Pathways Leading to Therapy-Related Myeloid Neoplasms
Michelle M. LeBeau, University of Chicago, Chicago, IL
Genomic Approaches to Cancer
Todd R. Golub, Broad Institute of MIT and Harvard, Cambridge, MA
Good Tregs and Bad Tregs in Colon Cancer
Khashayarsha Khazaie, Northwestern University Lurie Comprehensive Cancer Center, Chicago, IL
Heat Shock Proteins and Their Phamacologic Inhibitors in Cancer
Paul Workman, Institute of Cancer Research, Sutton, United Kingdom
How Does H. pylori Cause Gastric Carcinoma?
Masanori Hatakeyama, University of Tokyo, Tokyo, Japan
Imaging Choline Metabolism in Cancer
Kristine Glunde, Johns Hopkins University School of Medicine, Baltimore, MD
INK4-ARF (CDKN2A/B): Restricting Cellular Self-Renewal
Charles J. Sherr, St. Jude Children's Research Hospital, Memphis, TN
Lesson From Clinical Trials of Targeted Therapy in Cancer
George W. Sledge Jr., Indiana University Simon Cancer Center, Indianapolis, IN
The Leukemia Bone Marrow Niche
Dorothy A. Sipkins, University of Chicago, Chicago, IL
Liver Progenitor Cells and Liver Cancer
Nabeel M. Bardeesy, Massachusetts General Hospital Cancer Center, Boston, MA
Loss of the 14-3-3σ Tumor Suppressor Is a Critical Event in ErbB2-Mediated Tumor Progression
William Muller, McGill University, Montreal, QC, Canada
Lung Cancer Screening: The Long Way Towards a Public Health Screening Program for High-Risk Individuals: Where Are We Now in Europe?
Eugenio Paci, ISPO-Institute for Research and Prevention of Cancer, Florence, Italy
Met RTK Signaling, EMT, and Breast Cancer
Morag Park, Canadian Institutes of Health Research, Montreal, QC, Canada
Molecular Bases for APL Cure by Arsenic and Retinoic Acid
Hugues De The, University of Paris VII, Paris, France
Molecular Characterization of Circulating Tumor Cells
Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA
Mutant p53 and Metastasis
Karen H. Vousden, Beatson Institute for Cancer Research, Glasgow, United Kingdom
Mycn as a Driver and Therapeutic Target in Neural Cancers
William A. Weiss, University of California, San Francisco, CA
New Functions of APC in Regulating DNA Methylation Dynamics: Implications for Colorectal Cancer Initiation and Progression
David A. Jones, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
New Targets for Differentiation Therapy: APL and Beyond
Samuel Waxman, Mt. Sinai School of Medicine, New York, NY
Photoacoustic Tomography: Ultrasonically Breaking Through the Optical Diffusion Limit
Lihong Wang, Washington University, Saint Louis, MO
Principles and Practice of Molecular Pharmacodynamics in Cancer Drug Discovery
James H. Doroshow, National Cancer Institute, Bethesda, MD
Prostate Cancer Chemoprevention: Where Do We Go from Here?
Ian M. Thompson, Jr., UT Health Science Center, San Antonio, TX
Regulation of Cancer Metabolism by Hypoxia-HIF-VHL Signaling
Othon Iliopoulos, Massachusetts General Hospital, Charlestown, MA
Stem Cells, Cancer, and Cancer Stem Cells
Geoffrey M. Wahl, Salk Institute for Biological Studies, La Jolla, CA
Surprising Insights into BRCA1 Function(s)
David M. Livingston, Dana-Farber Cancer Institute, Boston, MA
SWI/SNF Complexes: Chromatin, Epigenetics, and Cancer
Charles W. M. Roberts, Dana-Farber Cancer Institute, Boston, MA
T Cell Engineering and the New Cancer Immunotherapies
Michel Sadelain, Memorial Sloan-Kettering Cancer Center, New York, NY
Targeting Cancer Metabolism: Hype, Hope, and MYC
Chi Van Dang, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
Targeting Oncogenic Ras in Cancer
Kevin M. Shannon, University of California, San Francisco, CA
Targeting the Ubiquitin-Proteasome System with Small Molecules
Randall W. King, Harvard Medical School, Boston, MA
Translational Control of Cancer
Nahum Sonenberg, McGill University, Montreal, QC, Canada
The Two Sides of Notch in Human Cancer
Warren S. Pear, University of Pennsylvania, Philadelphia, PA
Understanding the Clonal Structure and Evolution of Tumors With Next-Generation Sequencing
Samuel Aparicio, BC Cancer Research Center, Vancouver, ON, Canada
Undruggable Therapeutic Targets and How to Target Them
Jeffrey A. Toretsky, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
An Update on the Rapidly Emerging BAP1 Story: Connecting the Ubiquitin Epigenetic Code to Tumor Suppression
Frank J. Rauscher, III, The Wistar Institute, Philadelphia, PA
Using Genetically Engineered Mouse Models to Facilitate Cancer Drug Development
Leisa Johnson, Genentech, Inc., South San Francisco, CA
Using Genome-Wide Methylation Data in Epidemiologic Studies in Lung Cancer
Karl T. Kelsey, Brown University, Providence, RI
Using Quantitative Phosphoproteomics to Connect Genetics to Phenotype
Forest M. White, Massachusetts Institute of Technology, Cambridge, MA
Will the Real Li Fraumeni Syndrome Please Stand Up?
Louise C. Strong, The University of Texas MD Anderson Cancer Center, Houston, TX
|